GENFLEET-B (02595) Surges Over 8% in Morning Session as Company Releases Multiple Clinical Results for KRAS G12D Inhibitor

Stock News10-16 10:02

GENFLEET-B (02595) rose more than 8% in morning trading. As of press time, the stock was up 4.42% at HK$28.38, with a turnover of HK$50.3292 million.

On the news front, on October 15, GenFleet Therapeutics announced positive progress in multiple clinical studies of GFH375/VS-7375 (an oral KRAS G12D inhibitor) and released the latest data from the related research.

Currently, GFH375 has been granted Breakthrough Therapy Designation three times by the Center for Drug Evaluation of China's National Medical Products Administration, targeting KRAS G12D-mutant pancreatic cancer, non-small cell lung cancer (NSCLC), and colorectal cancer (CRC) respectively, and has entered two registrational Phase 3 studies for monotherapy in pancreatic cancer and NSCLC.

GenFleet's international partner Verastem Oncology is expected to launch a registrational Phase 3 study of VS-7375 in multiple combination regimens (combined with anti-EGFR therapy or chemotherapy) for first-line treatment of pancreatic ductal adenocarcinoma (PDAC) by the end of this year, with progression-free survival (PFS) and objective response rate (ORR) as dual primary endpoints and overall survival (OS) as a secondary endpoint. The study protocol has already reached consensus with the U.S. FDA.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1133902228?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-10-16 10:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1133902228","market":"other","top_or_hot":-1,"title":"GENFLEET-B (02595) Surges Over 8% in Morning Session as Company Releases Multiple Clinical Results for KRAS G12D Inhibitor","media":"Stock News","content":"<p>GENFLEET-B (02595) rose more than 8% in morning trading. As of press time, the stock was up 4.42% at HK$28.38, with a turnover of HK$50.3292 million.<br><br>On the news front, on October 15, GenFleet Therapeutics announced positive progress in multiple clinical studies of GFH375/VS-7375 (an oral KRAS G12D inhibitor) and released the latest data from the related research.<br><br>Currently, GFH375 has been granted Breakthrough Therapy Designation three times by the Center for Drug Evaluation of China's National Medical Products Administration, targeting KRAS G12D-mutant pancreatic cancer, non-small cell lung cancer (NSCLC), and colorectal cancer (CRC) respectively, and has entered two registrational Phase 3 studies for monotherapy in pancreatic cancer and NSCLC.<br><br>GenFleet's international partner Verastem Oncology is expected to launch a registrational Phase 3 study of VS-7375 in multiple combination regimens (combined with anti-EGFR therapy or chemotherapy) for first-line treatment of pancreatic ductal adenocarcinoma (PDAC) by the end of this year, with progression-free survival (PFS) and objective response rate (ORR) as dual primary endpoints and overall survival (OS) as a secondary endpoint. The study protocol has already reached consensus with the U.S. FDA.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GENFLEET-B (02595) Surges Over 8% in Morning Session as Company Releases Multiple Clinical Results for KRAS G12D Inhibitor</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGENFLEET-B (02595) Surges Over 8% in Morning Session as Company Releases Multiple Clinical Results for KRAS G12D Inhibitor\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-10-16 10:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>GENFLEET-B (02595) rose more than 8% in morning trading. As of press time, the stock was up 4.42% at HK$28.38, with a turnover of HK$50.3292 million.<br><br>On the news front, on October 15, GenFleet Therapeutics announced positive progress in multiple clinical studies of GFH375/VS-7375 (an oral KRAS G12D inhibitor) and released the latest data from the related research.<br><br>Currently, GFH375 has been granted Breakthrough Therapy Designation three times by the Center for Drug Evaluation of China's National Medical Products Administration, targeting KRAS G12D-mutant pancreatic cancer, non-small cell lung cancer (NSCLC), and colorectal cancer (CRC) respectively, and has entered two registrational Phase 3 studies for monotherapy in pancreatic cancer and NSCLC.<br><br>GenFleet's international partner Verastem Oncology is expected to launch a registrational Phase 3 study of VS-7375 in multiple combination regimens (combined with anti-EGFR therapy or chemotherapy) for first-line treatment of pancreatic ductal adenocarcinoma (PDAC) by the end of this year, with progression-free survival (PFS) and objective response rate (ORR) as dual primary endpoints and overall survival (OS) as a secondary endpoint. The study protocol has already reached consensus with the U.S. FDA.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02595","symbol_name":"劲方医药-B","start_time":0,"source_url":"","article_id":"1133902228","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1133902228","pubTimestamp":1792116145,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"GENFLEET-B (02595) rose more than 8% in morning trading. As of press time, the stock was up 4.42% at HK$28.38, with a turnover of HK$50.3292 million.On the news front, on October 15, GenFleet...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159938":"医药","02595":"劲方医药-B","KCAI":"KraneShares China Alpha Index ETF","09939":"开拓药业-B","BK1515":"抗疫概念","BK4588":"碎股","BK1161":"生物科技","BK4585":"ETF&股票定投概念","BK1574":"生物医药B类股","VXUS":"国际股票ETF-Vanguard"},"translate_title":"随着公司发布 KRAS G12D 抑制剂的多项临床结果，GENFLEET-B (02595) 早盘飙升超过 8%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1,"VXUS":1,"02595":1,"KCAI":1,"09939":1},"content_text":"GENFLEET-B (02595) rose more than 8% in morning trading. As of press time, the stock was up 4.42% at HK$28.38, with a turnover of HK$50.3292 million.On the news front, on October 15, GenFleet Therapeutics announced positive progress in multiple clinical studies of GFH375/VS-7375 (an oral KRAS G12D inhibitor) and released the latest data from the related research.Currently, GFH375 has been granted Breakthrough Therapy Designation three times by the Center for Drug Evaluation of China's National Medical Products Administration, targeting KRAS G12D-mutant pancreatic cancer, non-small cell lung cancer (NSCLC), and colorectal cancer (CRC) respectively, and has entered two registrational Phase 3 studies for monotherapy in pancreatic cancer and NSCLC.GenFleet's international partner Verastem Oncology is expected to launch a registrational Phase 3 study of VS-7375 in multiple combination regimens (combined with anti-EGFR therapy or chemotherapy) for first-line treatment of pancreatic ductal adenocarcinoma (PDAC) by the end of this year, with progression-free survival (PFS) and objective response rate (ORR) as dual primary endpoints and overall survival (OS) as a secondary endpoint. The study protocol has already reached consensus with the U.S. FDA.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1133902228","isCrawlerRequest":true}